论文部分内容阅读
目的观察重组人血管内皮抑素(恩度)联合放化疗和恩度联合化疗对非小细胞肺癌(NSCLC)的疗效及毒副反应。方法经病理证实43例NSCLC(Ⅱa~Ⅲb),按随机原则并参考病人意愿分为实验组(恩度+放化疗)24例和对照组(恩度+化疗)19例,化疗方案吉西他滨1 000 mg/m2,第1、8 d,顺铂20 mg/m2,第1~5 d,28 d 1周期,共3~4周期;恩度15 mg/d,同步每化疗周期的第1~14 d。放疗采用常规剂量分割2 Gy/d,总剂量60~66 Gy,与第一周期化疗同时进行。结果有2例出现明显心脏毒性或骨髓抑制,未完成治疗,只作毒性分析。实验组的完全缓解率高于对照组(P<0.05),中位无疾病进展时间分别为8.3月和4.7月,1年生存率分别为78.3%和55.6%(P<0.05),完全缓解病例主要集中在Ⅱa期鳞癌,实验组未明显增加治疗的毒副反应。结论恩度联合放化疗治疗非晚期肺鳞癌有较好近期疗效,延长无疾病生存时间及1年生存率,安全性好。
Objective To observe the curative effect and toxicity of recombinant human endostatin (Endo) combined with radiotherapy and chemotherapy and Endo combined with chemotherapy on non-small cell lung cancer (NSCLC). Methods Totally 43 cases of NSCLC (Ⅱa ~ Ⅲb) were confirmed by pathology. According to the randomized principle and referring to the wishes of the patients, 24 cases were divided into experimental group (n ° + radiotherapy and chemotherapy) and 19 cases of control group mg / m2, 1st and 8th d, cisplatin 20 mg / m2, 1st to 5th and 28th days for 3 to 4 cycles respectively; Endostatin 15 mg / d for 1st to 14th cycles of each chemotherapy cycle d. Radiotherapy using conventional dose division 2 Gy / d, the total dose of 60 ~ 66 Gy, with the first cycle of chemotherapy at the same time. Results There were 2 cases of significant cardiotoxicity or myelosuppression, did not complete treatment, only for toxicity analysis. The complete remission rate in the experimental group was significantly higher than that in the control group (P <0.05). The median time to progression-free disease was 8.3 months and 4.7 months respectively, and the 1-year survival rates were 78.3% and 55.6% (P <0.05) The main focus in stage Ⅱ a squamous cell carcinoma, the experimental group did not significantly increase the treatment of side effects. Conclusion Endo combined with radiotherapy and chemotherapy for non-advanced lung squamous cell carcinoma has better short-term curative effect, prolonging disease-free survival time and 1-year survival rate, and is safe.